ANPEP and myelodysplastic syndrome: NAPS showed clear distinctions between t(8;21) AML cases and these false-positive t(8;21) AML cases (except AML case 35) for markers from tube 1 of the EF AML/MDS panel, based on different patterns for HLA-DR (26%), and CD13 (25%) and differences in the SSC (26%) and forward scatter (FSC, 22%) parameters (Figure 6A).